Human myeloma cells acquire resistance to difluoromethylornithine by amplification of ornithine decarboxylase gene.

@article{Leinonen1987HumanMC,
  title={Human myeloma cells acquire resistance to difluoromethylornithine by amplification of ornithine decarboxylase gene.},
  author={Pekka E. Leinonen and L Alhonen-Hongisto and Romuald Laine and Olli A. J{\"a}nne and Juhani E J{\"a}nne},
  journal={The Biochemical journal},
  year={1987},
  volume={242 1},
  pages={199-203}
}
Stepwise increments of the concentration of 2-difluoromethylornithine (DFMO), a mechanism-based irreversible inhibitor of mammalian ornithine decarboxylase (ODC), resulted in a selection of cultured human IgG-myeloma cells (Sultan cell line) capable of growing in the presence of up to 3 mM-DFMO. This capacity was associated with 10-fold increase in ODC activity in the dialysed extracts of drug-resistant myeloma cells, markedly enhanced synthesis rate for ODC enzyme molecules, as revealed by a… CONTINUE READING